Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cardiomyopathy
- Sponsor
- Tongji Hospital
- Enrollment
- 4000
- Locations
- 1
- Primary Endpoint
- Heart transplantation confirmed by medical record
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Genetic mutations has been proved to be associated wth the onset of cardiomyopathy. In the present study, we intend to identify new related variants or genes. From March, 2003 to November, 2017, patients diagnosed as cardiomyopathy were consecutively recruited, and their sampled were drawn from peripheral blood. Paired control group were also enrolled. The whole exome sequencing was used to find out the variants associated with the onset of cardiomyopathy and its prognosis.
Investigators
Dao Wen Wang
Professor
Tongji Hospital
Eligibility Criteria
Inclusion Criteria
- •· Patients diagnosed as cardiomyopathy according to the definition of American Heart Association
Exclusion Criteria
- •Uncontrolled hypertension significant valvular disease
- •Mild ischemic heart disease
- •Significant systemic infection
- •Thyroid-induced cardiomyopathy
- •Excessive alcohol consumption
- •Precious cancer treatment including irradiation
- •Refusal to participate in the study
Outcomes
Primary Outcomes
Heart transplantation confirmed by medical record
Time Frame: up to 24 months
Heart transplantation within 24 months
Cardiovascular death confirmed by death comfirmation or interview with the relatives
Time Frame: up to 24 months
Death from cardiovascular causes and any unknown death unless there was another certain cause
Secondary Outcomes
- All cause death confirmed by death comfirmation or interview with the relatives(up to 24 months)
- Heart failure recurring confirmed by medical record(up to 24 months)